Inventiva SA
PAR:IVA
Inventiva SA
Common Shares Outstanding
Inventiva SA
Common Shares Outstanding Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Common Shares Outstanding | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Inventiva SA
PAR:IVA
|
Common Shares Outstanding
€52.5m
|
CAGR 3-Years
9%
|
CAGR 5-Years
14%
|
CAGR 10-Years
N/A
|
|
|
Valneva SE
PAR:VLA
|
Common Shares Outstanding
€162.4m
|
CAGR 3-Years
16%
|
CAGR 5-Years
12%
|
CAGR 10-Years
10%
|
|
|
Nanobiotix SA
PAR:NANO
|
Common Shares Outstanding
€47.4m
|
CAGR 3-Years
11%
|
CAGR 5-Years
16%
|
CAGR 10-Years
14%
|
|
|
Innate Pharma SA
PAR:IPH
|
Common Shares Outstanding
€81m
|
CAGR 3-Years
1%
|
CAGR 5-Years
1%
|
CAGR 10-Years
4%
|
|
|
G
|
Genfit SA
PAR:GNFT
|
Common Shares Outstanding
€49.8m
|
CAGR 3-Years
3%
|
CAGR 5-Years
5%
|
CAGR 10-Years
8%
|
|
|
Eurobio Scientific SA
PAR:ALERS
|
Common Shares Outstanding
€10m
|
CAGR 3-Years
-4%
|
CAGR 5-Years
-2%
|
CAGR 10-Years
13%
|
|
Inventiva SA
Glance View
Inventiva SA engages in the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis and related diseases. The company is headquartered in Daix, Occitanie and currently employs 100 full-time employees. The company went IPO on 2017-02-15. The firm focuses on the development of therapies in the area of oncology, fibrosis and rare diseases. The Company’s pipeline comprises a number of development programs, such as Clinical Pipeline, Preclinical Pipeline, AbbVie Collaboration and Boehringer-Ingelheim collaboration. Its drug candidates target at the treatment of non-alcoholic steatohepatitis (NASH), systemic sclerosis (SSc), various types of mucopolysaccharidosis (MPS), multiple myeloma, auto-immune disorders, as well as lung cancer, among others. In addition, the Company offers drug discovery services, ranging from target identification to preclinical nomination, in numerous areas, such as silico modelling, biology, screening, absorption, distribution, metabolism and excretion (ADME), pharmacology and histology.
See Also
What is Inventiva SA's Common Shares Outstanding?
Common Shares Outstanding
52.5m
EUR
Based on the financial report for Dec 31, 2024, Inventiva SA's Common Shares Outstanding amounts to 52.5m EUR.
What is Inventiva SA's Common Shares Outstanding growth rate?
Common Shares Outstanding CAGR 5Y
14%
Over the last year, the Common Shares Outstanding growth was 1%. The average annual Common Shares Outstanding growth rates for Inventiva SA have been 9% over the past three years , 14% over the past five years .
You don't have any saved screeners yet